Group 4C: HR+ Breast Cancer; Biomarkers; Clinical Trials; Targeted Therapies

Poster #1059: Circulating tumor cells (CTCs) dynamics after CDK4/6i for hormone-receptor positive (HR+) metastatic breast cancer (MBC): A biomarker analysis of the PACE randomized phase II study

Poster #1065: Efficacy analysis of CDK4/6 inhibitors (CDKi) + endocrine therapy (ET) treatment in hormone receptor-positive/HER2-negative (HR+/HER2-) advanced breast cancer (aBC): Biomarker analysis including chemoendocrine score (CES) by CDKi type in SOLTI-1801_CDK-PREDICT study

Sold out!

Waiting List

You're the first user in the Waiting List.


Jun 15 2023


10:00 am - 11:30 am

Zoom Webinar